Arianne Shadi Kourosh, MD, MPH, and Joe Niamtu, III, DMD, discuss adverse event reporting resources for COVID-19 vaccine filler reactions and the potential treatments when they occur.
The small incidence of COVID-19 vaccine induced filler reactions have raised new concerns pertaining to immunogenic activation and how to minimize potential risks.
Physicians discuss 2021 neurotoxin FDA-approvals, phase 3 trials, new indications, and introductions into the U.S. market.
Brian S. Biesman, MD; and Michael H. Gold, MD, discuss the state of injectables in 2021, including renewed interest in biostimulators, dermal fillers and neurotoxins hitting the US market, along with a focus on expanding indications.